Spontaneous Sinus Conversion of Permanent Atrial Fibrillation During Treatment of Hyperkalemia

Ji Hyun Yoon, MD, Da Hyun Jung, MD, Seung Kyo Park, MD, Ji Soo Park, MD, Jong-Youn Kim, MD, Pil-Ki Min, MD, Byung-Kwon Lee, MD, Young-Won Yoon, MD, Bum-Kee Hong, MD, Hyuck-Moon Kwon, MD, and Se-Joong Rim, MD

Cardiology Division, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea

Hyperkalemia is a common adverse effect of treatment for heart failure and is associated with high mortality and morbidity. The cardiac manifestations of hyperkalemia include various electrocardiogram changes. We describe a case of a 74-year-old woman with heart failure and permanent atrial fibrillation who reverted to normal sinus rhythm during recovery from hyperkalemia. (Korean Circ J 2012;42:65-68)

KEY WORDS: Hyperkalemia; Atrial fibrillation; Electrocardiography.

Introduction

Hyperkalemia is a common side-effect of heart failure treatment. The prevalence of hyperkalemia in the general population is unknown but reported to be 1-10% in hospitalized patients. The most common predisposing factors are impaired kidney function and drugs such as angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonists, and aldosterone antagonists. Cardiac manifestations of hyperkalemia are sometimes lethal with various presentations. The common electrocardiographic changes in patients with hyperkalemia include a tented T wave, PR interval prolongation, QRS widening, ventricular fibrillation, and asystole. It has been suggested that hyperkalemia may be associated with transient sinus conversion of atrial fibrillation (AF), and, indeed, we report here a case of hyperkalemia resulting in sinus conversion from permanent AF.

Case

A 74-year-old woman was admitted to the hospital for diarrhea and epigastric pain. She had a history of hypertension, diabetes mellitus, chronic kidney disease, dilated cardiomyopathy, and permanent AF for 5 years (Fig. 1). Echocardiography performed 3 months before admission revealed severe global left ventricular hypokinesia (ejection fraction=19% by Simpson’s method) and an enlarged left atrium (left atrial volume index=40 mL/m²). Her medications included digoxin (0.125 mg daily), warfarin (2 mg daily), ramipril (10 mg daily), furosemide (40 mg daily), spinolactone (25 mg daily), and carvedilol (25 mg daily).

On examination, her heart rate was 41 bpm, and blood pressure was 110/70 mm Hg. Heart sounds were regular, and there were no murmurs or thrills. An electrocardiogram (ECG) revealed junctional rhythm at a rate of 35 bpm and an 80 ms QRS duration (Fig. 2). Admission laboratory results showed severe hyperkalemia (serum potassium 8.3 mEq/L), high blood urea nitrogen (62.4 mg/dL), creatinine of 4.0 mg/dL, glucose of 248 mg/dL, and low sodium (131 mM) and hemoglobin (7.2 g/dL) levels. Arterial blood gas analysis on room air showed a pH of 7.400, pCO₂ of 41.6 mm Hg, pO₂ of 102.8 mm Hg, and HCO₃⁻ of 26.0 mmol/L.

The patient was immediately treated with intravenous calcium chloride, followed by intravenous glucose/insulin and a sodium bicarbonate infusion. On hospital day 2, the serum potassium level was 5.3 mEq/L and the ECG showed sinus bradycardia at a rate of 53 bpm with an 80 ms QRS duration (Fig. 3). On hospital day 3, the ECG revealed a normal sinus rhythm at a rate of 67 bpm, and the serum potassium level was within normal limits (4.3 mEq/L). The pa-
tient was discharged 6 days after admission, and the ECG at discharge showed normal sinus rhythm at a rate of 65 bpm with occasional premature ventricular complexes. At the 10 day and 1 month follow-ups, the ECG at an outpatient clinic had returned to AF and serum potassium levels were within the normal range.

Discussion

Hyperkalemia causes various ECG changes. In mild to moderate hyperkalemia, depression of conduction between cardiac myocytes results in prolongation of the PR and QRS intervals as potassium levels increase. Severe hyperkalemia induces suppression of sinoatrial and atrioventricular conduction, resulting in sinoatrial and atrioventricular blocks, escape beats, and escape rhythms. At extremely high serum potassium levels, the QRS complex is markedly widened and fused with the T wave, creating a sine-wave appearance on ECG.

Interestingly, previous reports have documented unusual cardiac manifestations related to hyperkalemia, including pacemaker capture and sensing failure, 9–11 loss of the delta wave in patients with Wolff-Parkinson-White syndrome, and transient sinus conversion.

Fig. 1. The electrocardiogram performed prior to admission was atrial fibrillation at a rate of 92 bpm.

Fig. 2. The electrocardiogram performed on admission revealed junctional bradycardia at a rate of 35 bpm and QRS duration of 136 milliseconds (K+ : 8.3 mEq/L).

Fig. 3. The electrocardiogram performed on hospital day 2 showed sinus bradycardia at a rate of 53 bpm and QRS duration of 80 milliseconds (K+ : 5.3 mEq/L).
of permanent AF during treatment for hyperkalemia. However, the mechanisms in these cases were not clearly defined.

In this case, the ECG on admission showed junctional bradycardia with a widened QRS complex. The ECG recovered to sinus bradycardia after the shift of potassium from the intracellular to extracellular space induced by intravenous glucose/insulin and sodium bicarbonate. Transmembrane permeability increases with the development of hyperkalemia and causes potassium influx into cells, which, in turn, causes decreased and shortened cellular action potentials by inactivating the sodium channel and delayed conduction between myocytes. As a result, hyperkalemia decreases excitability of atrial tissue, suppressing an irritant atrial ectopic focus and re-entrant circuit. Therefore, the ECG findings of junctional bradycardia with widening of the QRS complex on admission are explained by these mechanisms. Because the sinus node is less sensitive to high potassium level than atrial tissue, hyperkalemia suppresses sinus nodal function to a lesser degree than atrial tissue conduction. Therefore, sinus rhythm may recover earlier than AF activity in patients with permanent AF during treatment for hyperkalemia.

The maintenance duration of sinus rhythm that occurs during treatment for hyperkalemia remains undetermined and appears to vary according to clinical course. In a case report of hyperkalemia-induced sinus conversion, sinus rhythm was maintained for 3 months after normalization of serum potassium level and another case report of permanent AF with severe hyperkalemia described transient sinus conversion of only 16 minutes duration. In our patient, the ECG returned to AF after 10 days of normal serum potassium levels. Therefore, sinus rhythm during the recovery phase of hyperkalemia seems to eventually revert to AF within several weeks to months, so it is necessary to maintain proper treatment for AF.

In conclusion, other than well-known ECG features of hyperkalemia, restoration of sinus rhythm in patients with AF may occur during treatment for hyperkalemia, so it is important to maintain treatment for AF even after sinus conversion.

REFERENCES

1. Nyirenda MJ, Tang JI, Padfield PL, Seckl JR. Hyperkalaemia. BMJ 2009;339:b4114. doi:10.1136/bmj.b4114.
2. Paice B, Gray JM, McBride D, Donnelly T, Lawson DH. Hyperkalaemia in patients in hospital. Br Med J (Clin Res Ed) 1983;286:1189–92.
3. Moore ML, Bailey RR. Hyperkalaemia in patients in hospital. NZ Med J 1989;102:557–8.
4. Shemer J, Modan M, Ezra D, Cabili S. Incidence of hyperkalaemia in hospitalized patients. Isr J Med Sci 1983;19:659–61.
5. Evans KJ, Greenberg A. Hyperkalaemia: a review. J Intensive Care Med 2005;20:272–90.
6. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543–51.
7. Diercks DB, Shumaik GM, Harrigan RA, Brady WJ, Chan TC. Electrocardiographic manifestations: electrolyte abnormalities. J Emerg Med 2004;27:153–60.
8. Webster A, Brady W, Morris F. Recognising signs of danger: ECG changes resulting from an abnormal serum potassium concentration. Emerg Med J 2002;19:74–7.
9. Kahloun MU, Aslam AK, Aslam AF, Wilbur SL, Vasavada BC, Khan IA. Hyperkalaemia induced failure of atrial and ventricular pacemaker capture. Int J Cardiol 2005;105:224–6.
10. Schiraldi F, Giotto G, Paladino F. Hyperkalaemia induced failure of pacemaker capture and sensing. Resuscitation 2008;79:161–4.
11. Romeo E, Daito M, Santarpia G, et al. Hyperkalaemia–induced conversion of permanent atrial fibrillation to normal sinus rhythm: a case report. J Cardiovasc Med (Hagerstown) 2010;12:678–80.
12. Gogas BD, Liodromitis EK, Leftheriotis DJ, Flevari PG, Rallidis LS, Kremastinos DT. Instantaneous electrocardiographic changes and transient sinus rhythm restoration in severe hyperkalaemia. Int J Cardiol 2011;148:e40–2.
13. Mathew PK. Hyperkalaemia–induced conversion of chronic atrial fibrillation to normal sinus rhythm: a case report. Angiology 1979;30:143–6.
14. Fisch C, Knoebel SB, Feigenbaum H, Greenspan K. Potassium and the monophasic action potential, electrocardiogram, conduction and arrhythmias. Prog Cardiovasc Dis 1966;8:387–418.
15. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360–420.
16. Capucci A, Villani GQ, Aschieri D, Rosi A, Piepoli MF. Oral amioda-
ronin increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. Eur Heart J 2000;21:66-73.

17. Middlekauff HR, Wiener I, Stevenson WG. Low-dose amiodarone for atrial fibrillation. Am J Cardiol 1993;72:F75-81.

18. Gomes JA, Kang PS, Hariman RJ, El Sherif N, Lyons J. Electrophysiologic effects and mechanisms of termination of supraventricular tachycardia by intravenous amiodarone. Am Heart J 1984;107:214-21.

19. Kamiya K, Nishiyama A, Yasui K, Hojo M, Sanguinetti MC, Kodama I. Short- and long-term effects of amiodarone on the two components of cardiac delayed rectifier K(+) current. Circulation 2001;103:1317-24.

20. Naccarelli GV, Lukas MA. Carvedilol’s antiarrhythmic properties: therapeutic implications in patients with left ventricular dysfunction. Clin Cardiol 2005;28:165-73.